Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 7/20 | 0.34 |
| ▸ | MAOA | P21397 | 3/20 | 0.34 |
| ▸ | MAOB | P27338 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1911223 | 0.88 | FUCA1 (0.42) | FUCA1KDM1AMAOAMAOBMEN1 | |
| SCHEMBL319206 | 0.88 | FUCA1 (0.42) | FUCA1KDM1AMAOAMAOBMEN1 | |
| SCHEMBL319229 | 0.86 | FUCA1 (0.39) | FUCA1KDM1AMAOAMAOBMEN1 | |
| SCHEMBL10278488 | 0.86 | FUCA1 (0.39) | FUCA1KDM1AMAOAMAOBMEN1 | |
| SCHEMBL319110 | 0.86 | FUCA1 (0.38) | FUCA1KDM1AMAOAMAOBMEN1 | |
| SCHEMBL1911145 | 0.86 | FUCA1 (0.38) | FUCA1KDM1AMAOAMAOBMEN1 | |
| SCHEMBL12503269 | 0.85 | FUCA1 (0.36) | FUCA1KDM1AMAOAMAOBMEN1 | |
| SCHEMBL1911139 | 0.85 | FUCA1 (0.36) | FUCA1KDM1AMAOAMAOBMEN1 | |
| SCHEMBL1910730 | 0.85 | FUCA1 (0.36) | FUCA1KDM1AMAOAMAOBMEN1 | |
| SCHEMBL1910827 | 0.81 | MEN1 (0.35) | MEN1KMT2AALDH1A1HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109682-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | PIM1, GSK3A, GSK3B | FUCA1 3199/4885KDM1A 640/4885MAOA 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.